Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) traded up 8.2% on Wednesday . The company traded as high as $4.74 and last traded at $4.48, with a volume of 61,077 shares traded. The stock had previously closed at $4.14.

A number of equities research analysts recently weighed in on the company. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $28.00 price objective on shares of Catabasis Pharmaceuticls in a research note on Wednesday, May 25th. Wedbush restated an “outperform” rating and set a $17.00 price objective on shares of Catabasis Pharmaceuticls in a research note on Friday, August 12th. Zacks Investment Research cut Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a research note on Monday, July 18th. Finally, Cowen and Company restated a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Wednesday, June 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Catabasis Pharmaceuticls has an average rating of “Buy” and a consensus price target of $19.05.

The firm’s market capitalization is $68.91 million. The company’s 50 day moving average price is $4.71 and its 200-day moving average price is $4.86.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/catabasis-pharmaceuticls-inc-catb-trading-8-2-higher.html

Catabasis Pharmaceuticls (NASDAQ:CATB) last posted its earnings results on Thursday, August 11th. The company reported ($0.61) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.04. On average, equities analysts predict that Catabasis Pharmaceuticls Inc. will post ($2.47) EPS for the current year.

An institutional investor recently bought a new position in Catabasis Pharmaceuticls stock. Bridgeway Capital Management Inc. bought a new position in shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 27,700 shares of the company’s stock, valued at approximately $102,000. Bridgeway Capital Management Inc. owned approximately 0.18% of Catabasis Pharmaceuticls as of its most recent filing with the SEC. 66.58% of the stock is owned by institutional investors.

Catabasis Pharmaceuticls Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with MarketBeat.com's FREE daily email newsletter.